Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial

Sanofi SA (NASDAQ:SNY) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab) in chronic spontaneous urticaria (CSU).

  • The trial included CSU patients who don't respond to biologic treatment, Novartis AG (NYSE:NVS) / Roche Holdings AG's (OTC:RHHBY) Xolair (omalizumab). 
  • CSU is a severe form of hives, causing severe itching and swelling.
  • In the study, dupilumab couldn't significantly improve symptoms in Xolair-refractory patients.
  • The trial will be stopped for futility, although the antibody did show "numeric improvements" on itching and hive symptoms.
  • Related: Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis.
  • The previously reported Phase 3 trial, which evaluated CSU patients who were biologic-naïve, met its primary and all key secondary endpoints at 24 weeks.
  • Adding Dupixent to standard-of-care antihistamines significantly reduced itch and hives compared to antihistamines alone.
  • The companies are evaluating the next steps.
  • Price Action: SNY shares are trading higher by 0.49% at $53.13 during the premarket session on the last check Friday, while REGN stock closed at $626.72 on Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.